BioPharm International
August 01, 2018
Features
31
8
Biopharma seeks alternatives that meet the needs for next-gen biologic drug production.
August 01, 2018
From the Editor
31
8
Frustrated by slow market adoption, Gottlieb maps out new plan for biosimilar competition.
August 01, 2018
Features
31
8
More complex biologic samples must be evaluated to ever higher levels of specificity and sensitivity.
August 01, 2018
Features
31
8
Materials in contact with a drug must be fully characterized to ensure they do not negatively affect the safety and efficacy of the product.
August 01, 2018
Ask the Expert
31
8
The type of product, the packaging materials being used, and the process and materials used to manufacture the product will determine when E&L data should be submitted to regulators, says Susan J. Schniepp, executive vice-president, Post-approval Pharmaceuticals and distinguished fellow at Regulatory Compliance Associates.
August 01, 2018
Features
31
8
The changing regulatory and manufacturing environment is ushering in a new approach to drug development.
August 01, 2018
Cover Story
31
8
The quality of the cell lines used to manufacture biopharmaceuticals are crucial for the production of high-quality, stable biopharmaceuticals.
August 01, 2018
Issue PDF
31
8
Click the title above to open the BioPharm International August 2018 issue in an interactive PDF format.
July 02, 2018
Regulatory Beat
31
8
The agency is asking firms to discuss internal quality metrics efforts as part of the approval process for new medical products.